Eli Lilly disappointed market-watchers Wednesday with its 2015 forecast, which fell short of predictions that analyst have been tossing around. But Lilly executives said their numbers aren't so different from the Street's; it's just a matter of assumptions.
Eli Lilly started the new year by announcing it has closed its $5.4 billion acquisition of Novartis Animal Health, in the process expanding its Elanco animal health unit to 17 manufacturing sites and 14 R&D centers.
Eli Lilly is buying back into Adocia's pitch for a fast-acting insulin, reversing an earlier decision and signing a collaboration deal worth up to $570 million.
A war of words has broken out over the past week between Eli Lilly's Elanco animal health division and the company's hometown newspaper, the Indianapolis Star. At issue is an overriding question that weighs on the minds of pet owners worldwide: Are medications for dogs and cats really safe?
The plan for Eli Lilly's Cyramza has always been to rack up a string of approvals to vault the drug into blockbuster territory. As of Friday, the Indianapolis drugmaker is one step closer to achieving that goal.
A new rheumatoid arthritis pill from Eli Lilly and Incyte beat out placebo in a pivotal trial, the first late-stage success for a drug the companies hope can carve out a space in a crowded market.
Eli Lilly has stepped in to ink a worldwide license on Zosano Pharma's recipe for parathyroid hormone 1-34 dubbed ZP-PTH, which is delivered via its microneedle patch system to treat osteoporosis.
Eli Lilly's never-say-die strategy for Alzheimer's has inspired another high-risk campaign in the clinic. The shrinking pharma giant--about to be bumped from the top 10 by a growing Actavis--has launched its pivotal Phase II/III study of its BACE drug for Alzheimer's, newly partnered with AstraZeneca.
In biotech, here are the top 10 news stories of the year so far, based on web traffic.
When a new drug bursts upon an established drug class, the established players often wave away worries about market share. Sales for the whole class will grow, they say, because we'll have one more company on the street promoting it. And when it comes to Eli Lilly's Trulicity, the brand-new GLP-1 diabetes treatment, even Lilly says so.